LBH and prostate adenocarcinoma: Moreover, WNT was the second most enriched LBH-associated pathway in liver, pancreatic, rectal cancer; the third most enriched in esophageal (ESCA) and bladder (BLCA) cancer, and the fourth in prostate cancer (PRAD) (Supplementary Table S5).